3SBio Growth Driven By EPO With Shaky Future
This article was originally published in PharmAsia News
Executive Summary
Concerns raised by 3SBio's announcement of development delays for additional indications of its lead product EPIAO (recombinant human erythropoietin injection) are overshadowed by the product's growth potential, according to analysts
You may also be interested in...
3SBio Files For Approval For Interleukin-2 NuLeusin
SHANGHAI - 3SBio filed an application for the approval of NuLeusin with China's State FDA Nov. 10, hoping to make it the first product of its kind on the Chinese market, the Shenyang-based company announced
3SBio Files For Approval For Interleukin-2 NuLeusin
SHANGHAI - 3SBio filed an application for the approval of NuLeusin with China's State FDA Nov. 10, hoping to make it the first product of its kind on the Chinese market, the Shenyang-based company announced
3SBio CEO Jing Lou On Building An Integrated Biopharma Company In China: An Interview With PharmAsia News
Shenyang Sunshine Pharmaceutical Company Limited, now known as 3SBio, was incorporated in 1993 in Shenyang, China, and was the first Chinese biotech company to list on NASDAQ. The company develops and manufactures recombinant protein-based products, including erythropoietin stimulating agents such as the firm's flagship product EPIAO. 3SBio CEO and co-founder Jing Lou spoke recently with PharmAsia News' Shanghai bureau about building an integrated biopharmaceutical company in China, and the opportunities and challenges of competing in the global market.